Free Trial
NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

Veracyte logo
$30.50 -0.88 (-2.80%)
As of 04:00 PM Eastern

About Veracyte Stock (NASDAQ:VCYT)

Key Stats

Today's Range
$30.16
$31.38
50-Day Range
$28.47
$39.36
52-Week Range
$19.48
$47.32
Volume
1.07 million shs
Average Volume
865,214 shs
Market Capitalization
$2.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.60
Consensus Rating
Moderate Buy

Company Overview

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Veracyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

VCYT MarketRank™: 

Veracyte scored higher than 79% of companies evaluated by MarketBeat, and ranked 94th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Veracyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Veracyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Veracyte is -203.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Veracyte is -203.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Veracyte has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Veracyte's valuation and earnings.
  • Percentage of Shares Shorted

    6.68% of the float of Veracyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Veracyte has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Veracyte has recently increased by 22.54%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Veracyte does not currently pay a dividend.

  • Dividend Growth

    Veracyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.68% of the float of Veracyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Veracyte has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Veracyte has recently increased by 22.54%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Veracyte has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Veracyte this week, compared to 7 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,109.00 in company stock.

  • Percentage Held by Insiders

    Only 1.30% of the stock of Veracyte is held by insiders.

  • Read more about Veracyte's insider trading history.
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

Veracyte expands Decipher Prostate test availability
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
FY2026 EPS Estimates for Veracyte Boosted by Leerink Partnrs
Leerink Partnrs Has Negative Outlook of Veracyte Q2 Earnings
See More Headlines

VCYT Stock Analysis - Frequently Asked Questions

Veracyte's stock was trading at $39.60 on January 1st, 2025. Since then, VCYT stock has decreased by 23.0% and is now trading at $30.50.
View the best growth stocks for 2025 here
.

Veracyte, Inc. (NASDAQ:VCYT) announced its earnings results on Monday, February, 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.07. The biotechnology company had revenue of $118.63 million for the quarter, compared to analysts' expectations of $110.73 million. Veracyte had a negative net margin of 2.18% and a positive trailing twelve-month return on equity of 3.02%.
Read the conference call transcript
.

Veracyte subsidiaries include HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.

Veracyte's top institutional investors include Sumitomo Mitsui Trust Group Inc. (2.90%), AEGON ASSET MANAGEMENT UK Plc (0.84%), Assenagon Asset Management S.A. (0.63%) and Bank of New York Mellon Corp (0.32%). Insiders that own company stock include Rebecca Chambers, John Leite, Giulia C Kennedy, Bonnie H Anderson, Jonathan Wygant, Jonathan Wygant, Evan/ Fa Jones, John L Bishop, Jens Holstein, Muna Bhanji and Karin Eastham.
View institutional ownership trends
.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
2/24/2025
Today
4/30/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:VCYT
Employees
790
Year Founded
2006

Price Target and Rating

Average Stock Price Target
$42.60
High Stock Price Target
$51.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+40.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
44.62
P/E Growth
N/A
Net Income
$-74,400,000.00
Pretax Margin
-1.92%

Debt

Sales & Book Value

Annual Sales
$445.76 million
Cash Flow
$0.07 per share
Price / Cash Flow
442.29
Book Value
$14.30 per share
Price / Book
2.12

Miscellaneous

Free Float
76,493,000
Market Cap
$2.36 billion
Optionable
Optionable
Beta
2.03

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:VCYT) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners